Entity > Corporation > US > New York City New York > Kazia Therapeutics Limited
About Kazia Therapeutics Limited
Kazia Therapeutics Limited is an oncology-focused biotechnology company developing innovative anti-cancer drugs. Kazia Therapeutics Limited collaborates with leading scientists, clinicians and investors around the world.
Kazia Therapeutics Limited Welcomes Opportunities to Potential In-licensing of Development Candidates for Oncology Indications: Our primary focus is on small molecule therapies, with a preference for those that can be orally administered and handled under controlled ambient conditions. Kazia Therapeutics Limited are able to work in all cancer types, but with a focus on solid tumour indications. Kazia Therapeutics Limited are excited about development candidates with first-in-class or best-in-class potential, where there is clear target validation, compelling proof of concept in vivo, a mature GMP manufacturing process, and availability of some GLP toxicology data.
Kazia Therapeutics Limited’s Founding And Headquarters: Kazia Therapeutics Limited was founded in 1994 by Graham Kelly. Kazia Therapeutics Limited is currently headquartered in Hornsby, New South Wales, Australia.
Industry: Business & Industrial > Pharmaceuticals & Biotech
More information about Kazia Therapeutics Limited
| Company Attribute | Value |
| Address | StreetAddress: 300 Barangaroo Ave L 24, AddressLocality: Sydney, AddressRegion: New South Wales, PostalCode: 2000, AddressCountry: Australia |
| Founding Date | 1992 |
| Name | Kazia Therapeutics Limited |
| Number Of Employees | 8 |
| Revenue | $10,550,000 USD |
| Ticker Symbol | NASDAQ: KZIA |
| Url | kaziatherapeutics |
Kazia Therapeutics Limited
New York City, US
18 Sep 2023
Kazia Therapeutics Limited
Kazia Therapeutics (Biotechnology company)
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is an oncology-focused drug development company. Our lead program is paxalisib, which is being developed to treat glioblastoma (GBM), the most common and aggressive form of primary brain cancer in adults.
-
Headquarters : New South Wales, Australia
-
Subsidiaries : Glycotex, Inc., Novogen Research Pty Ltd., MORE
-
Stock price : KZIA (NASDAQ) $1.01 0.00 (0.00%)Sep 15, 4:00 PM EDT - Disclaimer
-
Founded : 1994